Surprise Knockback For Safinamide Gives Azilect A Boost
This article was originally published in Scrip
Just days after US WorldMeds signed up to commercialize the Parkinson's disease add-on therapy Xadago (safinamide) in the US, with US approval anticipated on its Mar. 29 PDUFA date, the product has been turned back by the FDA. The agency wants evaluation of the oral, once a day drug for its abuse liability and dependence/withdrawal effects before it can be approved, it said in a complete response letter.
You may also be interested in...
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.
After overcoming regulatory hurdles, Newron may have tough time competing in US against market stalwart Azilect; eight Parkinson's drugs are in Phase III trials.
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.